Biogen New Ventures takes part in Series A funding for Estuary Biotherapeutics: Can BIIB break above $240.99?

Traders Union
All News
Business & Wealth
Companies
Biogen stock rises 1% to $235.35

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Mykhailo Ihnatenko

16.10.2026

Biogen New Ventures takes part in Series A funding for Estuary Biotherapeutics: Can BIIB break above $240.99? — Biogen stock rises 1% to $235.35

Biogen New Ventures is backing gene therapy startup Estuary Biotherapeutics through its participation in the company's Series A financing. Shares are up 1% on the day at $235.35.

BIIB price prediction

24H -0.29%

$232.81

48H -0.25%

$232.9

7D 0.34%

$234.27

1M 6.88%

$249.54

3M 23.25%

$287.77

6M 30.38%

$304.4

12M 49.74%

$349.61

Current price: $233.48 0.8100 0.35%

Closed 10/19

Daily range 232.00

235.97

Weekly range 226.81

240.85

Loading...

Highlights

Biogen New Ventures invested in Estuary Biotherapeutics as part of the startup's Series A round focused on kidney disease gene therapies.
Shares are up 1% on the day at $235.35.
JP Morgan recently set a $300 target for Biogen stock, with 92 of 142 analysts rating it a buy.

Biogen New Ventures is taking part in the Series A funding round for Estuary Biotherapeutics. Estuary Biotherapeutics focuses on targeted gene therapies for autosomal dominant polycystic kidney disease. The company operates in drug manufacturers - general and carries a market value near $33.34 billion.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish structure holds as gains pause near weekly resistance

Shares of Biogen opened the session with a gap up from $232.81 to $236.46 before giving back part of those gains. Price remains above its MA-20, MA-50, and MA-200, maintaining a bullish daily structure. The RSI at 66.1 is approaching overbought territory, suggesting that the recent advance may be getting stretched. The nearest resistance is the weekly high at $240.99.

Upside risk dominates as five-day balance favors buyers

A close above $240.99 would indicate that buyers are willing to follow through on recent gains. After gapping higher at the open from $232.81 to $236.46, some of the early move was retraced over the session. Even so, over the next five trading days there is a 79% probability for further upside and a 21% chance of a pullback, with the anticipated trading range set between $225.78 and $244.91. A drop below $225.27 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that Biogen's acquisition of RayThera Inc furthered its expansion into immunology, with analysts highlighting a broadly bullish technical outlook. The company's recent investment in Estuary Biotherapeutics adds to this strategic momentum, and traders should closely watch the $240.99 resistance level for signs of continuation in the current uptrend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Mega deal ahead of IPO: How Nscale is preparing to go public

By Mikhail Vnuchkov
1 hour ago

Mega deal ahead of IPO: How Nscale is preparing to go public

Editors' Picks

Coldcard and Ledger attacks raise questions about hardware wallet security

By Kyle Torpey
2 hours ago

Coldcard and Ledger attacks raise questions about hardware wallet security

Editors' Picks

Who is Richard Heart, the HEX founder wanted by Interpol?

By Olena Litvinenko
21 hours ago

Who is Richard Heart, the HEX founder wanted by Interpol?

Editors' Picks

All Editors' Top Picks

Latest Biogen News

Biogen stock edges lower despite RayThera partnership

By Andreas Kristo
07.08.2026

Biogen stock edges lower despite RayThera partnership

Companies

Biogen stock trades up toward $207.56 with buyers in control above MA-20 and Kijun support

By Ezequiel Gomes
05.08.2026

Biogen stock trades up toward $207.56 with buyers in control above MA-20 and Kijun support

Companies

Biogen stock jumps 2.73 percent as Biogen kicks off Q2 2026 earnings webcast

By Dan Blystone
29.07.2026

Biogen stock jumps 2.73 percent as Biogen kicks off Q2 2026 earnings webcast

Companies

All Biogen News

Mikhail Vnuchkov
1 hour ago

Mega deal ahead of IPO: How Nscale is preparing to go public

Kyle Torpey
2 hours ago

Coldcard and Ledger attacks raise questions about hardware wallet security

Olena Litvinenko
21 hours ago

Who is Richard Heart, the HEX founder wanted by Interpol?

Eugene Komchuk
23 hours ago

Kaiko CEO: European stablecoins still cannot compete with USDT

Dmytro Kharkov
Yesterday

Adobe and AI: Is the creative software giant losing its edge?

Hanna Syniavska
5 min ago

Javier Blas: LNG prices hit 4-year high above $30 per mBtu

Elena Nikulina
15 min ago

Brent crude futures for late 2027 reach record highs, oil traders note

Pavlo Kot
30 min ago

Peter Spina: GLD shareholders cannot redeem shares for metal, only authorized participants have this right

Yulia Slavina
1 hour ago

BR surges 57 percent following consolidation, Alan Rogers notes

Ksenia Gerey
1 hour ago

China accumulates gold as a hedge against USD inflation, George Selgin notes

Top News

Pavlo Kot
1 hour ago

JPMorgan predicts Bitcoin will outperform U.S. stocks and gold over the next 15 years

JPMorgan predicts Bitcoin will outperform U.S. stocks and gold over the next 15 years

Ivan Andriyenko
1 hour ago

Gold prices fall as rising oil costs fuel inflation concerns

Gold prices fall as rising oil costs fuel inflation concerns

Andrey Mastykin
2 hours ago

BlackRock joins Jio IPO rush as institutional bids top $26 billion

BlackRock joins Jio IPO rush as institutional bids top $26 billion

Olga Shendetskaya
2 hours ago

Yemen fighting adds to oil supply risks as U.S. tackles tanker shortages

Yemen fighting adds to oil supply risks as U.S. tackles tanker shortages

Eugene Komchuk
3 hours ago

Visa to enable crypto payments at 175 million merchant locations

Visa to enable crypto payments at 175 million merchant locations

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

Ethereum price holds range as Glamsterdam upgrade fails to lift demand

Anton Kharitonov
Now

EUR/USD holds near 1.1230 as ECB and Fed expectations weigh on currency amid Treasury yield stability

Mykhailo Ihnatenko
Now

Nvidia stock tests $217 as AI infrastructure worries pressure tech sector

Parshwa Turakhiya
Now

Crypto.com and Novig challenge Missouri sports betting restrictions

Igor Krasulya
Now

French bond yields face pressure as unrest threatens budget plans

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.